Business
Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 11, 2020
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health,
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2021, ended June 30, 2020, at 4:15 pm Eastern time on Tuesday, August 11, 2020. \nManagement will host a conference call on Tuesday, August 11, 2020 at 4:30 pm eastern time to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. \nInterested parties can register for the conference by navigating to http://dpregister.com/10147021.Please note that registered participants will receive their dial in number upon registration.\nInterested parties without internet access or unable to pre-register may dial in by calling: \nPARTICIPANT DIAL IN (TOLL FREE):\n1-844-836-8741\nPARTICIPANT INTERNATIONAL DIAL IN:\n1-412-317-5442\nAll callers should ask for the Aethlon Medical, Inc. conference call. \nA replay of the call will be available approximately one hour after the end of the call through August 18, 2020. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10147021.\nAbout Aethlon Medical, Inc.\nAethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated \"Breakthrough Device\" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. \nAdditionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discov...